# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
RBC Capital analyst Conor McNamara maintains Bio-Rad Laboratories (NYSE:BIO) with a Outperform and raises the price target f...
Wells Fargo analyst Brandon Couillard maintains Bio-Rad Laboratories (NYSE:BIO) with a Equal-Weight and raises the price tar...
Bio-Rad Laboratories (NYSE:BIO) narrows FY2025 sales outlook from $2.541 billion-$2.606 billion to $2.567 billion-$2.593 billio...
Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $2.61 per share which beat the analyst consensus estimate of $1....